A montelukast Alzheimers clinical trial was completed in April 2024 by Intelgenx Technologies in Canada using their patented version of montelukast. However because the company was deeply in debt and its largest creditor Atai Life Sciences was demanding payment, Intelgenx applied in May 2024 in Canada to seek protection from its creditors. Atai Life Sciences took over the company and the clinical trial before the end of 2024.

A preliminary report by Intelgenx showed participants who took the highest dosage of 30 mg twice a day of their version of montelukast showed cognitive improvement. It would seem that, having this information and having ownership of this trial, Atai would want to come up with the final results. However Atai has been completely silent about the trial on their website. I suspect that Atai may be receiving financial incentives from an undisclosed pharmaceutical corporation to stop the final report, thus preventing another montelukast clinical trial from coming up with positive results.

https://www.clinicaltrialsarena.com/news/intelgenx-alzheimers-disease-trial/

 https://clinicaltrials.gov/study/NCT03402503